Theravance Biopharma (TBPH) director Susannah Gray receives new share and option grants
Rhea-AI Filing Summary
Theravance Biopharma director Susannah Gray received equity compensation in the form of shares and options. On June 12, 2026, she was granted 6,009 Ordinary Shares, bringing her direct holdings to 48,146 Ordinary Shares after the award.
On the same date, she also received a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each completed month of continuous service following the grant date, and any remaining unvested portion vests on the date of the next annual shareholder meeting if she remains in continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
GRAY SUSANNAH
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 13,398 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 6,009 | $0.00 | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 13,398 shares (Direct);
Ordinary Shares — 48,146 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Ordinary Shares granted: 6,009 shares
Shares held after grant: 48,146 shares
Option grant size: 13,398 shares
+3 more
6 metrics
Ordinary Shares granted
6,009 shares
Equity award on June 12, 2026
Shares held after grant
48,146 shares
Direct Ordinary Share holdings post-award
Option grant size
13,398 shares
Share Option (Right to Buy) underlying Ordinary Shares
Option exercise price
$16.64 per share
Conversion/exercise price of option
Option expiration
June 11, 2036
Expiration date of share option
Monthly vesting fraction
1/12 of option
Vests after each completed month of continuous service
Key Terms
Share Option (Right to Buy), Grant, award, or other acquisition, Ordinary Shares, exercise price, +1 more
5 terms
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 16.6400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous service financial
"provided the optionee remains in continuous service on such date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Theravance Biopharma (TBPH) director Susannah Gray receive in this Form 4 filing?
Director Susannah Gray received 6,009 Ordinary Shares and a share option for 13,398 Ordinary Shares. These awards are classified as a grant or award acquisition and represent equity-based compensation rather than open-market buying or selling of TBPH stock.
How does the Theravance Biopharma (TBPH) option granted to Susannah Gray vest over time?
The option vests as to 1/12 of the shares after each completed month of continuous service following the grant date. Any remaining unvested shares then vest on the date of the next annual shareholder meeting, provided she remains in continuous service with the company.
Is Susannah Gray’s Theravance Biopharma (TBPH) Form 4 transaction an open-market purchase or sale?
No. The Form 4 classifies both transactions with code A, meaning grant, award, or other acquisition. They represent compensation awards of shares and options, not open-market purchases or sales, and therefore do not reflect discretionary trading activity in TBPH shares.